Bayer to Invest $2.2 Billion in U.S. Pharma Manufacturing Expansion
Novartis AG ADR NOTA
News
Novartis to License Drug From China's Abogen in Up to $7.8 Billion Deal — Update
Novartis to License Drug From China's Abogen in Up to $7.8 Billion Deal
European Pharma Leaders Push for National Reforms to Boost Investment
Novartis to End ALS Trial Amid String of Study Failures
Novartis's failed trial for cholesterol drug leads to broad biopharma stock selloff
Novartis Down Over 12%, On Pace for Record Percent Decrease — Data Talk
Beneath the surface, the next stock-market leaders are getting ready to break out, says Morgan Stanley
Why the Dow is being dragged down by a Swiss company's bad news
Novartis's Latest Trial Setback Sinks Stock
Novartis Says Neuromuscular Drug Candidate Misses Goal in Late-Stage Trial
Novartis Shares Fall After Heart Drug Misses Target in Late-Stage Trial
Stocks to Watch: Ionis Pharmaceuticals, Novartis, Corvex
Novartis Says Pelacarsen Heart Disease Drug Missed Primary Endpoint — 2nd Update
Novartis Says Pelacarsen Heart Disease Drug Missed Primary Endpoint — Update
Novartis Says Pelacarsen Heart Disease Drug Missed Primary Endpoint
Novartis Up Nearly 6%, on Pace for Largest Percent Increase Since March 2023 — Data Talk
Novartis Shares Climb After Pill Hits Goals in Multiple Sclerosis Trials
Novartis Drug Meets Key Goal in Late-Stage Multiple Sclerosis Trials
Novartis Pauses Autoimmune Cell Therapy Studies After Deaths
United States